Who owns IDEAYA Biosciences, Inc. (IDYA)? Elite investor 13F holders
2 tracked elite investors reported holding IDEAYA Biosciences, Inc as of 2026-06-30, including Tudor Investment, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Tudor Investment | Ideaya Biosciences Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1687846.00 USD | 45287.000000 | Shares | add | Original filing |
| D.E. Shaw | Ideaya Biosciences Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 773837.00 USD | 20763.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.